Clinical Trials Browser

Phase 1 × Active not recruiting × immunotoxin HA22 × Clear all

NCT03805932 2025-07-24

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

Phase 1 Active not recruiting

18 enrolled 15 charts

Other hematologic neoplasm

Leukemia, Hairy Cell